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Multiple lines of research suggest that ammonia is harmful to the brain if the 
levels remain elevated for extended periods of time. Several decades ago, there 
was no testing or standard of care to monitor the effect of hyperammonemia (HA) 
on neurological function in urea cycle disorders (UCD), and the timing of HA 
encephalopathy is still not clear. Magnetic resonance imaging (MRI) was not done 
routinely, if at all, so it was not known what changes were occurring in the brain, 
during and after recovery from HA. Decades ago, a diagnosis of a UCD meant 
severe disability and early death. Earlier diagnosis, improved management, and 
nitrogen scavenger therapy have improved the lives and life span of patients with 
UCD. However, many patients suffer from learning difficulties under the umbrella 
“executive function” which comprises neurologically based skills involving mental 
control and self-regulation. The general agreement of the core elements of execu-
tive functions includes inhibition, working memory, and cognitive flexibility and is 
necessary in development of skills in reasoning, fluid intelligence, problem-solving, 
and planning. Our research focuses on the use of noninvasive neuroimaging 
coupled with neuropsychological testing to understand the complex relationship 
between ammonia, glutamine, cognitive function, seizures, and specifically impact 
on development of working memory.
Keywords: ammonia, EEG, glutamine, MRI, neuroimaging, urea cycle disorder
1. Introduction
The urea cycle disorders (UCD) represent one of the most common groups of 
inborn errors of metabolism, with an overall incidence of 1 in 30,000 [1, 2], and 
involve deficiency of one of six urea cycle enzymes or of a related cofactor or trans-
porter [3, 4]. The most common of these, ornithine transcarbamylase deficiency 
(OTCD), is the only disorder of ureagenesis inherited in an X-linked manner, 
with an estimated incidence of 1 in 70,000 [5]. Over 240 missense mutations have 
been identified in the OTCD gene but overall 400 including nonsense, frameshift, 
in-frame indels, splice site errors, and one in a regulatory domain [6, 7]. About 60% 
of hemizygous males harbor a mutation around the enzyme active site and present 
with hyperammonemic (HA) coma in the newborn period [8, 9]. The remaining 
40% of patients demonstrate more peripheral mutations in other parts of the gene, 
associated with less severe phenotypes and later onset presentation [10].
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A majority of children with OTCD have cognitive and motor deficits due to 
hyperammonemic episodes [8, 11–13]. Neonatal onset disease mortality rate is 
high. Prior to advances in recognition and treatment, it was not uncommon for 
survivors of neonatal onset disease to have intellectual disability, cerebral palsy, 
and seizures [14]. Neonatal survivors have a decreased IQ which may be as low as 
43. In males with partial deficiencies, disease onset is later, and outcome is better, 
although still associated with high mortality and morbidity with many individu-
als manifesting cognitive, motor, and psychiatric sequelae [15–17], in particular 
impaired working memory and other measures of executive function which are 
essential for performing well in school, vocations, and relationships. Treatment 
of OTCD involves a combination of protein restriction (which is also a restriction 
in nitrogen, leading to ammonia accumulation) and medications that invoke an 
alternative pathway of waste nitrogen excretion [18, 19]. Females heterozygous 
for OTCD have a variable phenotype and display a broad range of symptoms from 
apparently asymptomatic to fully affected, owing to both allelic heterogeneity and 
differential X-inactivation patterns.
A common presumption for years has been that approximately 85% of hetero-
zygous females are asymptomatic based on history, whereas the remainder show 
symptoms ranging from behavioral and learning disabilities and protein intolerance 
to cyclical vomiting, stroke-like episodes, and hyperammonemic coma [20–23]. 
Symptomatic women who harbor mutations seen in the neonatal onset disorder 
in hemizygous males [10] may develop HA due to skewed X-inactivation. There is 
therefore a range of residual enzyme capacities and urea synthetic capacities that 
result in this variation [24]. However, advances in neuroimaging and the work of 
the Urea Cycle Disorders Consortium (UCDC) have demonstrated that many of 
these previously presumed asymptomatic females have similar brain structural, 
biochemical, and cognitive biomarkers seen in those who are clinically impacted, 
yet they may be mild under conditions of low demand. More obvious symptoms 
were uncovered when cognitive demand increases or there is superimposed illness 
or stressor [25].
2. Pathophysiology of the UCDs
Ammonia is a product of the metabolism of proteins and other compounds, 
and it is required for the synthesis of essential cellular compounds. However, a 
five- to tenfold increase in ammonia in the blood induces toxic effects in most 
animal species, with alterations in the function of the central nervous system. 
Ammonia is a normal constituent of all body fluids. At physiologic pH, it exists 
mainly as ammonium ion. Reference serum levels are less than 35 mmol/L (outside 
the newborn period, where higher levels are seen). Excess ammonia is excreted as 
urea, which is synthesized in the liver through the urea cycle. Sources of ammonia 
include bacterial hydrolysis of urea and other nitrogenous compounds in the 
intestine, the purine-nucleotide cycle and amino acid transamination in skeletal 
muscle, and other metabolic processes in the kidneys and liver. Increased entry of 
ammonia to the brain is a primary cause of neurological disorders associated with 
HA, such as congenital deficiencies of urea cycle enzymes, hepatic encephalopa-
thies, Reye syndrome, several other metabolic disorders, and some toxic encepha-
lopathies [26–28].
On the basis of studies in animal models and other preclinical model sys-
tems, several mechanisms of ammonia neurotoxicity at the molecular level have 
been proposed.
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While the exact pathophysiology remains unclear, current theories include (1) 
glutamine accumulation, with associated impaired cerebral osmoregulation, and 
(2) glutamate/N-methyl D-aspartate (NMDA) receptor activation, with resultant 
excitotoxic injury and energy deficit [26–30]. The WM is preferentially affected in 
proximal UCD, and the extent of injury has been shown to depend upon the dura-
tion of HA coma and the interval between coma and death [28].
Acute ammonia intoxication in an animal model leads to increased extracellular 
concentration of glutamate in the brain and results in activation of the NMDA 
receptor. Activation of this receptor mediates ATP depletion and ammonia toxicity; 
blocking the NMDA receptor with dizocilpine (MK-801) prevents both phenomena. 
The ATP depletion is due to activation of Na+/K+-ATPase, which, in turn, is a conse-
quence of decreased phosphorylation by protein kinase C. Activation of the NMDA 
receptor may account for seizures seen in some patients during acute HA [29].
High levels of ammonia in the brain also induce other metabolic changes that are 
not mediated by activation of the NMDA receptor and thus are not involved directly 
in ammonia-induced ATP depletion or neurotoxicity. These include increases 
in brain levels of lactate, pyruvate, glutamine, and glucose, with concomitant 
decreases in brain glycogen, ketone bodies, and glutamate [30].
Chronic HA is associated with an increase in inhibitory neurotransmission as 
a consequence of two factors. The first involves the downregulation of glutamate 
receptors secondary to excessive extrasynaptic accumulation of glutamate. The sec-
ond mechanism implies increased GABAergic tone resulting from benzodiazepine 
receptor overstimulation by endogenous benzodiazepines and neurosteroids. These 
changes likely play a role in central nervous system features of intellectual function, 
decreased consciousness, and coma [26, 30].
In the brain, glutamine represents a storage depot for nitrogen, binding excess 
ammonia and offering a short-term buffering of excess ammonia in patients with 
HA, likely as a protective mechanism. It is these high levels of glutamine in the 
brain that are also hypothesized to be neurotoxic and one of the factors leading to 
injury (UCDC unpublished). Brain astrocytes are key players in the interactions of 
glutamine and ammonia via the Gln/Glu cycle (Figure 1).
Figure 1. 
The glutamine-glutamate cycle. Reprinted with permission from Pediatric Health, 2008, 2(6):701–713.
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When ammonia is not adequately detoxified by the hepatic urea cycle, there is 
an increase in scavenger amino acids, including glutamine. Ammonia entering the 
brain is rapidly incorporated into the formation of glutamine by glutamine syn-
thetase, present in the astrocyte. Glutamine concentrations increase in hyperam-
monemic states. While not measured directly, indirect measures with 1H magnetic 
resonance spectroscopy (MRS) studies of patients with urea cycle disorders have 
demonstrated elevations of the glutamine/glutamate complex [30]. Glutamine has 
been implicated in hyperammonemic encephalopathy. It has been shown that a rise 
in plasma glutamine levels precedes HA. There is a sustained positive correlation 
between plasma glutamine and ammonia levels.
Inhibition of glutamine synthetase in hyperammonemic rats by treatment 
with enzyme inhibitors prevents the rise in cortical glutamine levels and cortical 
water content [31]. Clearance of synaptic glutamate by glial cells is required for the 
normal function of excitatory synapses and to prevent neurotoxicity. This process 
occurs in the atrocity, which takes up synaptic glutamate and returns glutamate 
to the neurons in the form of glutamine, a non-neuroactive amino acid that the 
neurons subsequently reconvert to glutamate via the action of mitochondrial 
phosphate-dependent glutaminase.
2.1 Short-term clinical effects of HA
Clinical signs of HA may occur at concentrations >60 micromol/L and are very 
individual as some patients may tolerate higher levels before symptoms are noticed. 
The short-term changes may include initially anorexia, irritability, lethargy, som-
nolence, disorientation, vomiting, and asterixis (flapping tremor). As symptoms 
progress and ammonia is not lowered, cerebral edema, coma, herniation and death 
[30]. In the acute stages, there is increased blood brain barrier permeability, leading 
to depletion of intermediates of cell energy metabolism. On an anatomic level, there 
is disaggregation of microtubules [29].
2.2 Chronic effects of HA
Chronic effects of HA include alterations in axonal development as well as 
alterations in brain amino acid and neurotransmitter levels. Electrophysiologic 
effects of HA include direct effects on inhibitory postsynaptic potentiation (IPSP). 
Neurotransmission is impacted due to increased extracellular glutamate levels and 
downregulation of AMPA-kainate receptors, enhanced tryptophan uptake, elevated 
quinolinic acid levels, and enhanced NMDA activity. Activation of NMDA receptors 
increases calcium in postsynaptic neurons which binds to calmodulin and activates 
neuronal nitric oxide (NO) synthase, increasing NO, which activates guanyl-
ate cyclase, increasing cyclic guanine monophosphate (cGMP), part of which is 
released to the extracellular space [31, 32]. Activation of this glutamate- NO-cGMP 
pathway may be involved in some forms of learning.
Recent reports indicate that guanylate cyclase and cGMP are important in learn-
ing and memory; induction of LTP is the molecular basis of some forms of learning 
and memory [33]. Because glial cells also have these receptors, the excessive gluta-
mate leads to glial cell swelling, which seems to protect the neurons from excitotoxic 
injury. Studies in spf mouse models of OTC and other animal models of HE show 
neuropathological evidence of excitotoxic neuronal cell death which suggests that 
overactivation of NMDAR is a feature of urea cycle disorders [34] and may be age 
dependent [35].
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3. What are the cognitive implications of HA on the brain?
A proportion of individuals with OTCD have a wide spectrum of neuropsycho-
logical complications including developmental delay, intellectual disability, and 
executive function deficits [36]. Most adult-onset patients remain asymptomatic, 
until they present with rapid decline in mental status and subsequently chronic 
encephalopathy [36, 37].
Fluctuating HA may cause delirium, confusion, and incoherent speech. In addi-
tion to subsequent regression, lack of attention leads to unemployment and intro-
verted behavior [37]. Waisbren et al. demonstrated that nearly all asymptomatic 
156 women with OTCD attained a full-scale intelligence quotient (IQ ) of 102 ± 16. 
Among 25 men, the full-scale IQ measured was 101 ± 21. No differences were noted 
between the verbal and performance scores. In addition, in 27% of females and 
33% of males, working memory deficiency was observed as a constant finding. 
The ammonia concentration and its duration appear to be key determinants of the 
long-term outcome [37].
3.1 Long-term sequelae of HA: Executive function
Executive function (EF) is the ability to control and regulate actions and 
thoughts [38]. It includes processes such as working memory, self-regulation, and 
inhibitory control.
Executive functions are a set of cognitive processes and competencies that 
control behavior and learning. It is an umbrella term which comprises neuro-
logically based skills involving mental control and self-regulation. The general 
agreement of the core elements of executive functions includes inhibition, 
working memory, and cognitive flexibility [38, 39]. These elements are highly 
interrelated, and the interplay of these processes is vital in flexible, goal-directed 
behaviors. From the core elements of basic executive functions, higher-order 
executive functions such as reasoning, fluid intelligence, problem-solving, and 
planning are built [40].
Historically, executive functioning has been thought to be regulated by the 
prefrontal cortex of the frontal lobes; however reviews found indications for the 
sensitivity, but not for the specificity, of executive function measures to the fron-
tal lobe [41]. Both the frontal brain regions and other structures of the brain are 
involved and necessary for successful application of these skills.
Individuals are not born with executive function skills, but rather are born with 
the potential to develop them. With any genetic or environmental insult to the 
brain, the executive functions and prefrontal cortex are one of the first to suffer 
and suffer disproportionately. The disruption of the brain architecture can seriously 
delay or impair the development of executive functioning [38].
To date, most evaluations of EF rely on parents’ reports such as the Behavior 
Rating Inventory of Executive Function Preschool (BRIEF-P) form, which may not 
capture the development of executive skills to its full expression [42].
EF has been previously studied using task-based functional MRI (fMRI) scans, 
which can be difficult to adapt for children [43]. Instead, multiple studies have 
relied on resting state functional MRI [44]. Reineberg et al. investigated differences 
in brain connectivity in relation to individual performances during different EF 
behavioral tasks [45]. However, to our best knowledge, resting state fMRI has not 
been applied to characterize EF-related brain connectivity differences in children, 
especially at a young age (2–5 years old).
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4.  How can neuroimaging help us probe markers of neurological 
dysfunction in IEMs?
Multiple studies using multimodal MRI suggest its value in the recogni-
tion of microscopic anatomic damage that precedes clinical symptoms in many 
inborn errors of metabolism and neurodegenerative disorders. Depending 
upon the type of imaging study, it may answer a different question regarding 
the pathology, biochemistry, or physiology. Neuroimaging may detect subtle 
abnormalities that can be correlated with neurocognitive abnormalities even in 
asymptomatic OTCD heterozygotes. The neuroimaging/neurocognitive stud-
ies we performed as part of the UCDC focused on adolescents and adults with 
OTCD. Our collective studies demonstrated that OTCD heterozygous females 
have changes in function of the prefrontal cortex (PFC) in association with an 
altered neurocognitive profile in working memory, executive functioning, and 
attention [46].
fMRI can allow us to understand how the brain constructs neural networks to 
perform cognitive tasks, probe how these networks are altered in brain disorders, 
and allow us to follow recovery. Magnetic resonance spectroscopy using hydrogen 
(1H) or carbon (13C) allows us to probe both static and dynamic changes in brain 
metabolism [47]. The benefits of neuroimaging using MRI are the ability to view 
the brain in the three orthogonal views, the lack of radiation exposure, and the 
ability to target the organ or pathology being studied. In addition, high-perfor-
mance MR hardware is available resulting in faster scans and higher resolution 
with higher field.
4.1 Use of neuroimaging to assess brain injury in UCDs
Neuroimaging in recent years has come to encompass many different modalities 
that can be combined in a single imaging session to gain complementary informa-
tion regarding the brain’s structural, functional, and metabolic dimensions.
A typical routine structural MRI protocol includes not only T1- and T2-weighted 
sequences but also, in most academic and teaching hospitals, fluid attenuation 
inversion recovery (FLAIR) and voxel-based morphometry (VBM) or other ability 
to measure tissue volume from acquired structural images on a clinical scanner. 
Diffusion weighted and diffusion tensor imaging (DWI and DTI) are used to study 
microstructural variance in WM fiber tracts [48], and proton magnetic resonance 
spectroscopy is used to measure brain metabolism in static and dynamic models 
[47]. Multimodal assessment batteries and data fusion give investigators a complex 
and varied perspective into the structural, functional, and biochemical parameters 
of the central nervous system in IEMs [49].
4.2 What MRI modalities are available and what do they measure?
4.2.1 Magnetic resonance imaging (MRI)
MRI interrogates tissue water protons via differential populations of proton 
spins that result when a biological sample is placed in a strong magnetic field. Using 
MRI, one can define brain anatomy and characterize gray matter and WM micro-
structural and macro-structural changes. These are read as signal abnormalities on 
T1- and T2-weighted images which correspond with the specific tissue pathologies. 
With MRI one can detect damage at a macroscopic level. One must remember 
that MRI findings can lag behind clinical changes and stages of disease as well as 
recovery processes.
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4.2.2 Fluid-attenuated inversion recovery
Fluid-attenuated inversion recovery imaging is usually a routine part of most 
radiology clinical imaging sequences. Diffusion tensor imaging (DTI) is used due to 
its sensitivity in detecting increases in interstitial water content. Such applications 
include imaging brain tumors, demyelinating diseases (i.e., multiple sclerosis), 
metabolic WM disease cerebral infarcts, and gliotic scars.
4.2.3 Diffusion weighted imaging and diffusion tensor imaging
Diffusion MRI is another MRI method which allows fine mapping of the dif-
fusion process of molecules (i.e., water) in biological tissues. DWI and DTI can be 
used in vivo noninvasively. DWI and DTI techniques are focused on the fact that 
molecular diffusion in tissues is not free but, rather, is impacted by obstacles, such 
as macromolecules and cell membranes (myelin). By using DTI, water molecule 
diffusion patterns can inform about microscopic details regarding myelin integrity 
and architecture.
DTI relates image intensities to the relative mobility of water molecules in the 
tissue. It can also imply direction of the motion [48]. In general, areas that have a 
relatively high mean diffusion appear dark on the diffusion weighted MRI images. 
Diffusion MRI can also be used to make inferences about WM architecture since the 
diffusion of water corresponds to cell geometry in axons [48].
Cytotoxic edema in contrast follows sodium/potassium pump failure, often due 
to energy metabolism failure due to ischemic insult. It is quick and can occur within 
minutes of the onset of ischemia and can produce increased brain tissue water of up 
to 3–5%. In HA, cytotoxic edema also results. Therefore, DTI can be used in patients 
with UCD at baseline to assess whether patients differ with respect to WM integrity. 
DTI has a role in measuring functional connectivity differences between control 
groups and patients and to follow up patients over time to monitor disease progres-
sion, recovery, or impact of therapies [50]. It is a very good technique to also look 
at rapid fluxes in water content such as during a HA episode in a patient with UCD 
and allows follow-up noninvasively during recovery and/or with introduction of a 
therapeutic agent.
The most commonly used indices for the measurement of anisotropic diffusions 
by DTI include the relative anisotropy measure, fractional anisotropy (FA), and 
the volume ratio indices. These indices provide quantitative measurements of the 
changes of WM integrity in brain regions that are affected by diseases.
We have used DTI techniques together with advanced fiber tracking algorithms, 
to evaluate the 3D trajectories of neural tracts. This has allowed us to model WM 
neural connectivity in UCDs. DTI was used to determine whether there are WM 
microstructural abnormalities in partial OTCD that could underlie the cognitive 
phenotype. Our focus on WM alterations was based on prior neuropathology stud-
ies in HA. These studies have shown WM is almost exclusively affected. There is 
also a relationship between Gln toxicity and WM damage [51]. Anisotropy was cal-
culated by standard methods, from the eigenvalues of the diffusion tensor by using 
the FA metric. After comparison between UCD patients and age-matched control 
groups, we established that FA of the frontal WM was significantly decreased in 
patients with UCD compared to the age-matched controls. This, in turn, is indica-
tive of changes in WM microstructure (Figure 2). Additionally, we found an inverse 
relationship between FA and disease severity that was not age dependent. Based on 
this, we could conclude that MR imaging in OTCD may be normal in patients with 
late-onset disease, heterozygotes, or those not in hyperammonemic crisis at the 
time of the study.
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DTI was much more sensitive to changes in WM microstructural differences 
than fast spin echo (FSE) T2-weighted imaging for detecting abnormalities in 
normal-appearing WM. We also found that the degree of the abnormality cor-
related with degree of cognitive deficits. The location of the deficits in the frontal 
WM is highly significant as this area is important in the connectivity of fibers vital 
to executive function, working memory, and attention.
4.3  Progressive WM injury predicts cognitive decline with the most pronounced 
effects on processing speed and executive function
With our research we have shown DTI evidence of WM injury in motor tracts 
that subserve executive attention and working memory and can correlate measures 
of FA with specific working memory tasks. These changes result from WM tract 
disruption and related cortical disconnection. Quantitative data on the WM micro-
structure provide a more direct measurement of brain tissue integrity than standard 
MRI sequences.
4.3.1 WM damage in OTCD
Neuropathological findings have been extensively examined in patients who 
have died due to urea cycle disorders. These findings shared pathology with other 
more common conditions such as hepatic encephalopathy as well as hypoxic isch-
emic encephalopathy. Previous autopsy and, more recently, neuroimaging studies 
suggest that OTCD results in a predilection for WM injury. And in patients several 
months prior to death after surviving a neonatal presentation, neuropathological 
findings consisting of cortical atrophy, ventriculomegaly, gliosis with Alzheimer 
type II astrocytes, spongiform changes at the gray/white junction, ulegyria, and 
spongiform changes in the deep gray nuclei-basal ganglia and thalamus have been 
reported in the literature [52–55].
Neuroimaging studies which have been performed several months after a neona-
tal hyperammonemic event, months later in neonatal coma survivors, are consistent 
with these pathological findings, correlating with hypomyelination of WM, myelin-
ation delay, cystic changes of the WM, and gliosis of the deep gray matter nuclei. 
The original reports were small case series using clinical CT initially and then, only 
Figure 2. 
Decreased FA in the anterior cingulate. The decrease in FA is most significant in patients with OTCD who are 
symptomatic, but note also FA decreased in those “asymptomatic” patients as compared to controls without any 
urea cycle disorder.
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later, MRI. Survivors of prolonged hyperammonemic coma had severe anatomic 
abnormalities including ventriculomegaly and cortical atrophy. Today, these severe 
findings are rarely encountered if patients are diagnosed promptly, and duration of 
hyperammonemia is shortened.
4.4 Functional MRI and UCD research (fMRI)
The basic premise behind fMRI is the increase in blood flow to the local vascu-
lature that accompanies neural activity in the brain. This leads to a local reduction 
in deoxyhemoglobin. An increase blood flow occurs without an increase of similar 
magnitude in oxygen extraction.
Deoxyhemoglobin is paramagnetic; it alters the T2*-weighted magnetic resonance 
image signal and serves as the source of the signal for fMRI [56]. Coupling between neu-
ral activity and changes in blood flow was first reported in 1890 (Roy and Sherrington) 
[56]. By using fMRI, one can observe how the brain is functioning and what areas of 
brain are activated while a person is performing a specific task. It can allow unmasking of 
regional vulnerability, circuitry, and recovery of function after damage or intervention.
4.5 Magnetic resonance spectroscopy
MRS is another clinical sequence that provides noninvasive analytic method 
of identifying and measuring the individual brain chemicals present in various 
brain regions. 1H–MR spectroscopy is widely used in clinical practice to provide 
information on brain metabolites. The major metabolites that can be seen include 
choline (Cho), creatine (Cr), N-acetyl aspartate (NAA), glutamine (Gln), and the 
osmolytes: myoinositol (mI) and taurine (Taur). Metabolites that can be detected 
have a unique frequency resonance that is termed the chemical shift. The chemi-
cal shift is reported as parts per million (ppm). The advantage of this measure in 
ppm is that it is the same at any magnetic field strength. The basis of the signal 
derives from Larmor frequency and coupling. The frequency of individual nuclei 
is compared to a reference compound called tetramethylsilane (TMS). The MRS is 
read from right to left. The metabolites that are disrupted in OTCD include Gln, 
Cho, and mI [57, 58]. One can quantitate the metabolites by either using in house 
software or using a commercially available program such as linear combination 
modeling or LCModel [59].
The magnetic resonance (MR) signal detectable is directly proportional to the 
concentration of the nuclei in the prescribed voxel. Because the brain is mainly 
composed of water which has a concentration of 55.5 mmol per gram, this must be 
subtracted in the analysis as the concentration of other chemicals such as NAA or 
PCr is on the order of 0.015 and 0.5 mmol per gram of tissue. Common voxel sizes 
used in MRS are from 1 to 5 mm3.
Both the size and shape of a peak seen on a spectrum are due to the contribution 
of five attributes:
1. The concentration of nuclei.
2. The T1 and T2 relaxation times of the metabolite. These are also affected by 
the TR (relaxation time) and TE (echo time) of the MRS sequence as certain 
metabolites at low concentration may only be seen best at low TE.
3. Magnetic inhomogeneity across the sample. This can be corrected to some ex-
tent by a process called shimming. This implies the process by which the main 
magnetic field (Bo) is made more homogenous by applying small electrical 
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currents. This can be done passively, as many vendors have automated shim-
ming packages on the scanners, or manually.
4. Another consideration, especially in the case of 1H MRS in the UCD, is the 
presence of overlapping peaks since several metabolites in whole or in part 
may have overlapping peaks at a certain ppm.
5. Whether the line is expected to be single or a multiplet. This is determined by 
the chemical structure J coupling effects.
Some of these principles are explained below.
MR proton spectroscopy has great utility in evaluation of brain metabolic distur-
bances. Although a nonspecific pattern (elevated Cho, depressed NAA) is common 
in many types of brain disease, short echo time (TE) MRS (i.e., TE < 30 msec) can 
reveal more specific metabolic signatures. It is also useful to focus on the temporal 
changes of chemicals rather than only what is abnormal. Furthermore, temporal 
changes on subsequent exams can help support or refute the benefit of ongoing 
therapeutic measures. A simple single voxel technique boasts better signal-to-noise 
ratios (SNR) and allows shorter TE options than multivoxel technique.
Voxel size is always a consideration, since there is a balance between signal-
to-noise ratio and tissue specificity; ideally, it should be as large as possible to 
achieve satisfactory SNR but small enough to target the area of interest. Generally, 
a 2 × 2 × 2 cm (2 cm3) voxel is sufficient; voxels smaller than 1 cm3 are unlikely to 
be worthy of the acquisition time it would require to achieve reasonable SNR. Voxel 
location and echo times should be selected based on the suspected and/or discov-
ered disease patterns. We typically perform ultrashort (TE 14, TR 1500; STEAM 
technique), short (TE 35, TR 1500-2000; PRESS technique), and intermediate (TE 
144, TR 1500-2000; PRESS) or long (TE 288, TR 1500-2000; PRESS) echo time 
sequences. Examples of metabolites that are best seen at short echo include gluta-
mine and glutamate.
In the case of glycine at 3.55 ppm, it is necessary to obtain at least one MRS data 
point using an intermediate (i.e., 144 msec) or long (i.e., 288 msec) echo time to 
remove the spectral contamination of mI that is also around 3.5 ppm.
When are longer echo times preferred? Longer echo times improve diagnostic 
specificity in disorders such as maple syrup urine disease (MSUD) by eliminating 
the normal background macromolecular signal that can hide branched-chain amino 
and ketoacid peaks.
The noninvasive detection of elevated brain glutamine by 1H MRS has also been 
shown to be a useful biomarker in chronic hepatic encephalopathy [60–62]. We 
have observed clinically, and it has been shown that glutamine has been implicated 
in hyperammonemic encephalopathy. A rise in plasma glutamine levels precedes 
HA [60–62]. The importance of glutamine in this process is further strengthened 
by the relationship between HA, neurologic dysfunction, and cerebral spinal fluid 
glutamine concentrations observed in patients with hepatic encephalopathy.
The UCDC presented the largest series of adult patients with OTCD who were 
imaged using 1H MRS at 3 T and discuss the utility of advanced imaging in under-
standing the underlying mechanisms of dysfunction [57]. 1H MRS studies have 
demonstrated elevations in Gln and decreases in mI and Cho in patients who are 
clinically symptomatic [51]. We showed with 1H MRS decreased mI is also an impor-
tant biomarker and also seen in females who describe themselves as asymptomatic 
[57]. We have hypothesized that the decrement of mI might constitute a useful 
biochemical marker with which to discriminate females with a partial deficiency.
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4.5.1 13C MRS
Although 1H MR spectroscopy is a sensitive tool to detect biochemical abnor-
malities in individual patients, in vivo 13C MR spectroscopy can reliably be used to 
quantitate distinct signals from glutamate and glutamine. Unambiguous assign-
ment of these metabolites can contribute to a better understanding of the patho-
genesis and treatment of brain dysfunction in UCDs. With the use of carbon 13 
(13C) MR spectroscopy, abnormalities in cerebral glutamate metabolism have been 
noted in patients with chronic hepatic encephalopathy. Therefore, the next step was 
to use this technique to investigate cerebral glutamate turnover rate in patients with 
partial OTCD.
This method allows study of glutamate neurotransmission which is carried out 
by a glial neuronal process that includes the oxidation of glucose and the Gln/Glu 
cycle [63]. The metabolic model predicts that under conditions of elevated plasma 
ammonia, the increase in the rate of Gln synthesis is stoichiometrically coupled to 
increase in the uptake of the anaplerotic substrates CO2 and ammonia with con-
current efflux of Gln from the brain. Furthermore, studies in hyperammonemic 
rats suggest that only a fraction of Gln is used to synthesize GABA via Glu. The 
remainder passes through the neuronal TCA cycle. Bluml et al. have previously 
shown that there is disturbed neurotransmitter Glu/Gln cycling in chronic hepatic 
encephalopathy [63, 64]. In their studies, Glu enrichment was decreased and Gln 
enrichment was increased.
5.  Beyond ammonia: relationship of dysregulation of glutamatergic and 
GABAergic neurons in patients with HA and occurrence of seizures
Despite decades of research, the mechanisms leading to neural injury in HA are 
still not well understood. Ammonia toxicity is not necessarily an adequate explana-
tion for the degree of cognitive dysfunction seen in patients with argininosuccinate 
synthase (ASS), argininosuccinate lyase (ASL), and arginase deficiency (ARG). 
ASS is also referred to as citrullinemia.
Recent studies by our group and others, however, have shown that HA exposure 
alters several amino acid pathways and neurotransmitter systems, cerebral energy 
metabolism, nitric oxide synthesis, oxidative stress, and signal transduction path-
ways which all increase the risk for seizures [30, 65].
Epilepsy had previously been considered an infrequent manifestation in urea 
cycle disorders, but our longitudinal study (LS) of infants with UCD at a single 
site (Children’s National Health System) found subclinical electrographic seizures 
(ES) (detected on EEG without clinical manifestations) to be surprisingly common 
during acute hyperammonemic episodes [66].
This unanticipated finding was particularly identified in neonates with HA. This 
new finding raises the question of whether seizures play an important role in the 
etiology of neurocognitive deficits in UCD and whether seizures could afford a 
biomarker that correlates with brain damage in these disorders.
We have observed ES developing in patients in whom HA rebounded following 
discontinuation of ammonia scavengers. During HA, the brain is vulnerable to 
injury as a result of increased permeability and alterations in energy metabolism. In 
this small cohort, we observed that children with evidence of ES had abnormal MRI 
scans and/or adverse neurodevelopmental outcomes. This is consistent with what 




HA episodes are critical periods in which to intervene in order to prevent 
long-term cognitive disability. In neonates and children, HA episodes occur in the 
context of a developing brain that already has vulnerabilities as a result of normal 
remodeling, synaptogenesis, and ion channel development. It is also the period in 
life recognized to be at highest risk for seizures. It is possible that seizures in HA 
infants and children with UCD are an early biomarker of perturbed metabolism 
and, left untreated, may contribute to brain injury and subsequent intellectual and 
other developmental disabilities.
Considerable evidence shows that HA compromises brain energy metabolism 
which predisposes the patient to seizures due to neuronal depolarization in asso-
ciation with lower energy. The seizures then in turn further lower brain energy, 
setting in motion a physiologic cycle: HA → lower ATP → depolarization/increased 
vulnerability to seizures → frank seizures (or, at least, ES) → further lowering of 
ATP → more seizures (or ES) [68].
5.1 Seizures in UCD
While there is a paucity of investigation of the incidence/prevalence of seizures 
in UCD, one early study evaluated 11 EEG tracings of 4 infants, irrespective of 
clinical seizure status [69]. This small study identified epileptiform EEG alterations 
and hypothesized that they may be a characteristic manifestation of UCD. Later, 
a retrospective analysis of EEG tracings and head CT scans in 49 UCD patients 
revealed EEG abnormalities during a clinically stable period that were predomi-
nantly observed in patients with abnormal CT scans [70].
In agreement with these reports, our group has identified that patients with 
distal UCD (where ammonia levels are not as elevated as in proximal disorders) 
have a high frequency of epilepsy and cognitive dysfunction, raising the possibility 
that seizures may be associated with other biochemical abnormalities in distal UCD 
[36, 71]. Additionally, we have shown that disrupted neural networks underlying 
working memory are a consistent finding in UCD patients with mild as well as 
severe symptoms [25, 46]. These studies strengthen the importance of understand-
ing the incidence/prevalence of epilepsy in patients with UCDs and if and how 
this may affect later cognitive function. It further suggests that patients may be 
undertreated if we focus solely on ammonia-lowering agents and fail to recognize 
and treat concurrent seizures, as there are clearly other factors, such as disturbed 
mitochondrial function and oxidative stress, implicated in ammonia-induced 
neurotoxicity [68, 72–74].
5.1.1 Animal models of UCD and seizures
Both myoclonic and tonic–clonic seizures have been reported in the OTCD 
spf-ash mouse, an animal model of late-onset UCD with variable phenotype and 
severity. One study showed that the seizures were linked to the neurotoxic effect of 
HA on astrocytes, which increased and desynchronized astrocytic Ca2+ signaling 
and compromised the ability to buffer extracellular potassium. Using an animal 
model of inducible HA, the NAGS knockout (NAGSko) mouse, develops HA 
within a few hours of withdrawal of effective treatment with N-carbamylglutamate 
and L-citrulline (NCG + Cit) [75]. Studies in these mice demonstrated that they 
manifested seizures during HA but unexpectedly also had seizures during baseline 
recording when blood ammonia levels were normal. In this study, EEG seemed to be 
a sensitive measure of detecting neuronal dysfunction from HA and suggested its 
use as an early biomarker of its damaging effects.
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The common hypothesis as to how ammonia may lead to seizures is based on 
the idea that reducing ammonia in the blood will reduce the influx into astrocytes, 
thereby inhibiting the glutamine synthetase enzyme. This is the basis of ammonia 
lowering agents in clinical use. However, the work of Rangroo-Thrane et al. chal-
lenged that idea by showing that this only may worsen the neurological condition 
by increasing neuronal exposure to both [NH4
+] and [K+]. They have shown that 
failure of buffering potassium in astrocytes actually is the critical mechanism that 
contributes to ammonia neurotoxicity. Using awake, intact mice that were induced 
to have HA, this research group reported that when ammonia was blocked from 
entering the astrocyte via the potassium transporter Na+-K+-2Cl− cotransporter 
isoform 1 (NKCC1), seizures developed. They also conclude that a therapeutic 
intervention should work by blocking this pathway by inhibiting NKCC1 [75].
To determine the incidence of seizures in our UCD cohorts, we conducted a 
data mining study of six children who were enrolled in the UCDC since 2003 and 
who had continuous video EEG (cVEEG) during a HA episode and sufficient data 
to abstract. We accessed their data including clinical information, MRI scans, and 
metabolic laboratory results including ammonia and glutamine levels. We found 
that seizures occurred in neonates with UCD even when ammonia and glutamine 
levels had returned to normal. We further found that interburst interval duration 
(the time between brain activity and silences) correlated with ammonia levels. 
During periods of HA, the duration of electrical silence was prolonged, and the EEG 
pattern could be used to predict elevated ammonia levels (Figure 3). A prolonged 
interval was also correlated with cerebral dysfunction and an abnormal follow-up 
MRI showing injury (Figure 4) [76]. cVEEG therefore can be a useful tool for 
managing infants with HA and may be essential for seizure management, especially 
for infants in deep metabolic coma. Features of the EEG appeared predictive of 
short-term cognitive outcome and structural injury on MRI in this cohort.
Figure 3. 
EEG patterns change with concentration of ammonia from normal neonate (a) to increased interburst 
intervals, in this case also showing focal seizure (arrows) (b) to more significant suppression of brain activity 




Selected axial brain MR images at the level of the basal ganglia at day of life 14 (a–d) and 18 (e). 
Heterogeneous cerebral hyperperfusion improves over time between exams. (a and e) reduced diffusion is 
present showing hyperintense signal in the callosal splenium and genu, sagittal stratum, internal capsules, 
frontal WM, and, to a lesser extent (with partial pseudonormalization), the cerebral cortex and deep gray 
nuclei in correlation with the ADC map (not shown). (b) Hyperintensity on T1WI and (c) hypointensity 
onT2WI (d) are present extensively throughout most of the cerebral cortex, and mild signal changes are present 
affecting the cerebral deep gray nuclei. The cortical signal changes on the T1 and T1WI represent laminar 
necrosis. The unmyelinated cerebral WM demonstrates excessive T1 and T2 prolongation. There is mild diffuse 
cerebral volume loss with prominent sulci and ventricles.
6. Conclusions
Our understanding of the neurocognitive challenges of OTCD has been 
improved with the study of advanced MR imaging techniques; however, many 
issues remain unresolved. We are beginning to understand the neural networks 
impacted and have been able to correlate imaging findings with specific cognitive 
outcomes. We now need to scale it back to determine the earliest markers of brain 
injury. New findings of electrographic seizures in neonates with UCD raise ques-
tions of whether seizures play an important role in the etiology of neurocognitive 
deficits in UCD and whether changes on the EEG could afford a biomarker that 
correlates with brain changes in these disorders. Future studies are directed towards 
studying a more diverse group of UCD patients during baseline as well as during 
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HA events. Pattern recognition to inform the structural and biochemical changes on 
MRI will allow us to move towards precision management where neuromonitoring 
may inform moment to moment changes in clinical management.
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